Company intelligence / Profile preview
Alfresa Pharma
Osaka, Japanalfresa-pharma.co.jp ↗
- Ownership
- Public · 2784
- Development stage
- Other
01
Overview
Alfresa Pharma manufactures and develops pharmaceuticals, including branded and generic drugs, active pharmaceutical ingredients (APIs), and contract development and manufacturing services. It also handles medical devices and diagnostics, maintaining ISO13485:2003 certification for several sites. In 2023, it merged with Sannova, expanding its production and R&D capabilities[1]. Clinical results are primarily within established commercialized products.
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Alfresa Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alfresa Pharma.